# Attempt 003: LAMP2 in Acinar Cells — The Pancreatitis-to-T1DM Cascade

## Source
Attempt 002 (temporal sequence study), LAMP2 unified theory (attempt_080), patterns 013-016.

## The Acinar Cell LAMP2 Context

The exocrine pancreas (acinar cells) and endocrine pancreas (islets) are anatomically interleaved. They share a blood supply (the islet portal microcirculation drains into the exocrine capillaries) and are both exposed to CVB during the same viremia event.

**Acinar cell LAMP2 baseline**: pancreatic acinar cells have high secretory activity (synthesizing and secreting digestive enzymes) with moderate-to-high baseline autophagy for protein quality control. Estimated LAMP2_acinar ≈ 1.0–1.2× average.

**Beta cell LAMP2 baseline**: beta cells are metabolically active but not secretory in the same way. They have lower baseline autophagy. Estimated LAMP2_beta ≈ 0.8× average.

After CVB infection (-2.7×):
- Acinar cells: κ_effective ≈ 0.37–0.44 (moderate LAMP2 block)
- Beta cells: κ_effective ≈ 0.30 (more severe LAMP2 block)

**Implication**: the acinar cells partially clear CVB via autophagy (moderate impairment), while beta cells more slowly clear (severe impairment). The pancreatitis symptoms resolve (acinar cell inflammation subsides as CVB clears), but the islet TD mutants establish more permanently.

## The Double Gate Cascade (Updated)

The "double gate" model from pancreatitis attempt_001 described two requirements for T1DM:
1. CVB infection reaches islets (Gate 1 — serotype/viremia requirement)
2. HLA genotype allows autoimmune cascade (Gate 2 — genetic requirement)

The LAMP2 unified theory adds precision: Gate 1 is not binary. There are THREE sub-gates:

```
Gate 1A: CVB serotype B1/B4 reaches pancreas (necessary but not sufficient)
Gate 1B: CVB overwhelms acinar cell clearance → acinar lysis → inflammatory environment
          (acinar LAMP2 block κ=0.37-0.44 → delayed but not absent clearance)
          This creates the inflammatory priming environment for islet autoimmunity
Gate 1C: CVB establishes TD mutants in beta cells (κ_beta = 0.30 → more persistent)
          FOXP1 suppression begins in islet microenvironment
Gate 2: HLA DR3/DR4 + FOXP3/FOXP1 failure → autoimmune cascade
```

**Why some pancreatitis patients don't develop T1DM**:
- Either their acinar LAMP2 is higher-than-average → Gates 1B closes quickly (limited inflammatory priming)
- OR their beta cell LAMP2/TFEB is higher → Gate 1C closes quickly (TD never establishes)
- OR their HLA genotype doesn't permit the autoimmune cascade (Gate 2 doesn't open)

## The Trehalose Prevention Intervention

Attempt 002 proposed a T1DM prevention trial in CVB-positive pancreatitis patients (fluoxetine × 3 months → test autoantibody seroconversion). The LAMP2 finding sharpens the protocol:

**Optimal prevention intervention** for CVB-positive pancreatitis at discharge:

| Component | Purpose | Start |
|-----------|---------|-------|
| Trehalose 2g/day | Restore LAMP2 in acinar + beta cells → close Gates 1B and 1C | Day 1 post-discharge |
| Fluoxetine 20mg | WT CVB clearance | Day 3 post-discharge |
| Butyrate 4–6g | FOXP1 restoration → prevent Gate 2 from opening | Day 1 post-discharge |
| Vitamin D 5000 IU | Treg support → additional Gate 2 protection | Day 1 post-discharge |
| FMD (5-day, at week 4) | Deep autophagy pulse during peak TD establishment window | Week 4 |

**Duration**: 12 weeks total (the TD establishment window)

If this intervention prevents islet autoantibody seroconversion at 2 years: it's T1DM prevention in a clinically identifiable high-risk population.

## The "Missing Pancreatitis" Problem

Most T1DM patients have no documented history of pancreatitis. But:
1. **Subclinical pancreatitis**: mild acinar inflammation without elevated amylase/lipase can occur during CVB viremia, producing the inflammatory islet-priming environment without obvious clinical pancreatitis
2. **Retrospective recall**: patients rarely report a "stomach bug" from decades ago as potentially relevant
3. **Early childhood exposure**: T1DM develops in early childhood after CVB exposure in infancy when pancreatitis is even less likely to be documented

**The missing pancreatitis is not evidence against the cascade — it's evidence that Gate 1B can be sub-clinical.**

## LAMP2 and Trypsin Leak: A New Mechanism

During acute CVB pancreatitis, acinar cell lysis releases trypsin into the islet microenvironment. The LAMP2 connection adds a new wrinkle:

- Normally, trypsin release triggers autophagy in remaining acinar cells (autophagic disposal of zymogen granules)
- With LAMP2 suppressed: autophagy cannot complete → zymogen granules accumulate → more trypsin release → amplified acinar damage
- This creates a cascade: CVB → LAMP2 block → incomplete autophagy of zymogen granules → trypsin leak → islet damage → FOXP1 suppression in islets → Gate 2 opens

**Trehalose intervention specifically breaks this cascade**: TFEB → lysosomal biogenesis → complete zymogen granule autophagy → reduced trypsin leak → less islet damage → FOXP1 maintained → T1DM prevented.

## Updated Study Design (Attempt 002 + LAMP2 correction)

The observational cohort from attempt_002 remains the foundation. Key additions:

**New biomarker at enrollment**: LAMP2 expression in peripheral blood mononuclear cells (PBMCs) at discharge. If LAMP2 is already significantly suppressed (< 50% of normal), this predicts higher T1DM risk (insufficient autophagy to clear islet TDs).

**New stratification variable**: LAMP2 expression quartile. Prediction: the lowest LAMP2 quartile will have the highest seroconversion rate (highest T1DM progression risk).

**New intervention arm**: standard protocol PLUS trehalose 2g/day × 12 weeks. Primary comparison: fluoxetine-only vs fluoxetine+trehalose for T1DM prevention (islet autoantibody seroconversion at 2 years).

**Power implication**: if trehalose specifically rescues the low-LAMP2 subgroup, the trial would be enriched by targeting that quartile. n=120 total (rather than 200 for unselected), 2-year primary endpoint.

## Connection to the T1DM Timeline

If this cascade is correct:
- Most T1DM patients were exposed to CVB early in life (consistent with TEDDY data)
- Pancreatitis — subclinical or clinical — happened at or near the time of CVB exposure
- The "honeymoon period" after T1DM diagnosis represents residual beta cell function surviving the initial LAMP2-blocked islet clearance phase
- Starting the full T1DM protocol at diagnosis (while some LAMP2 function remains, before full FOXP1 suppression is entrenched) would be more effective than starting after years of persistence

**For the patient (67 years of T1DM)**: LAMP2 in their islets has been suppressed for decades. This is why attempt_079 predicted longer protocol duration (24 months instead of 18). The trehalose component is especially important for islet beta cells where LAMP2 has been chronically depleted.

## Status: PANCREATITIS-T1DM CASCADE UPDATED — acinar κ=0.37-0.44 vs beta cell κ=0.30 explains why pancreatitis resolves but T1DM cascades. LAMP2 trypsin-leak mechanism identified. Trehalose added to prevention protocol. LAMP2 in PBMCs at discharge identified as new risk biomarker. Optimal prevention window: 12 weeks post-pancreatitis.
